Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2011-11-08 M&A Activity
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is a slide deck related to the proposed acquisition of Synthes, Inc. by Johnson & Johnson. It references Rule 425 under the Securities Act of 1933, which pertains to communications related to mergers and acquisitions. The text mentions the filing of a registration statement on Form S-4 and a proxy statement/prospectus related to the acquisition. The content focuses on the merger proposal, integration plans, and strategic benefits of the acquisition. There are no financial statements or detailed financial analysis present, but rather presentation materials and commentary about the merger. This aligns with the definition of M&A Activity filings, which include announcements and documents related to merger proposals or takeover bids. Therefore, the appropriate classification is TAR (M&A Activity). The document length (6263 characters) supports that this is a substantive document rather than a brief announcement or report publication notice.
2011-11-08 English
PRIMARY DOCUMENT
Director's Dealing
2011-11-04 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which is typically used for communications related to mergers and acquisitions. The text discusses the proposed acquisition of Synthes, Inc. by Johnson & Johnson, references filings such as Form S-4 and a proxy statement/prospectus related to the acquisition, and provides information on where to find these documents. It also contains forward-looking statements and risk factors related to the transaction. There is no actual financial data or detailed report content here; rather, it is an announcement and communication about the merger process and related filings. This fits the category of Merger & Acquisition (MA) filings, which include merger communications and related announcements under Rule 425.
2011-11-03 English
PRIMARY DOCUMENT
Director's Dealing
2011-11-02 English
Regulatory Filings 2011
Regulatory Filings
2011-11-01 English
PRIMARY DOCUMENT
Director's Dealing
2011-10-31 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.